Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

首圖

「Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,」 said Nadim Ahmed, President, Hematology and On......